CA3129438A1 - Tyk2 pseudokinase ligands - Google Patents

Tyk2 pseudokinase ligands Download PDF

Info

Publication number
CA3129438A1
CA3129438A1 CA3129438A CA3129438A CA3129438A1 CA 3129438 A1 CA3129438 A1 CA 3129438A1 CA 3129438 A CA3129438 A CA 3129438A CA 3129438 A CA3129438 A CA 3129438A CA 3129438 A1 CA3129438 A1 CA 3129438A1
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
compound
solvate
acceptable salt
c6alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3129438A
Other languages
English (en)
French (fr)
Inventor
Raju Mohan
John Nuss
Jason Harris
Shendong Yuan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ventyx Biosciences Inc
Original Assignee
Ventyx Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventyx Biosciences Inc filed Critical Ventyx Biosciences Inc
Publication of CA3129438A1 publication Critical patent/CA3129438A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3129438A 2019-02-07 2020-02-07 Tyk2 pseudokinase ligands Pending CA3129438A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962802642P 2019-02-07 2019-02-07
US62/802,642 2019-02-07
PCT/US2020/017314 WO2020163778A1 (en) 2019-02-07 2020-02-07 Tyk2 pseudokinase ligands

Publications (1)

Publication Number Publication Date
CA3129438A1 true CA3129438A1 (en) 2020-08-13

Family

ID=71947508

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3129438A Pending CA3129438A1 (en) 2019-02-07 2020-02-07 Tyk2 pseudokinase ligands

Country Status (12)

Country Link
US (1) US20220135567A1 (cg-RX-API-DMAC7.html)
EP (1) EP3920931A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022519696A (cg-RX-API-DMAC7.html)
KR (1) KR20210124409A (cg-RX-API-DMAC7.html)
CN (1) CN113677347A (cg-RX-API-DMAC7.html)
AU (1) AU2020218267A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021015616A2 (cg-RX-API-DMAC7.html)
CA (1) CA3129438A1 (cg-RX-API-DMAC7.html)
IL (1) IL285429A (cg-RX-API-DMAC7.html)
MX (1) MX2021009555A (cg-RX-API-DMAC7.html)
SG (1) SG11202108619SA (cg-RX-API-DMAC7.html)
WO (1) WO2020163778A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS66346B1 (sr) 2018-10-22 2025-01-31 Alumis Inc Inhibitori tyk2 i njihova upotreba
SG11202110523XA (en) 2019-03-26 2021-10-28 Ventyx Biosciences Inc Tyk2 pseudokinase ligands
CN114929226B (zh) * 2019-11-08 2024-09-27 温缇克斯生物科学公司 Tyk2假激酶配体
IL301385A (en) * 2020-09-16 2023-05-01 Alumis Inc TYK2 inhibitors and their use
CN117043164A (zh) * 2021-01-19 2023-11-10 安锐生物医药科技(广州)有限公司 咪唑并哒嗪或吡唑并嘧啶化合物和组合物
KR20240111312A (ko) 2021-10-25 2024-07-16 카이메라 쎄라퓨틱스 인코포레이티드 Tyk2 분해제 및 이의 용도
CN121941683A (zh) * 2023-09-22 2026-04-28 杭州多域生物技术有限公司 含氮并环类化合物、其药物组合物及其应用
WO2025165746A1 (en) * 2024-01-30 2025-08-07 Ennovathera, Inc. Certain chemical entities, compositions, and methods
WO2025168035A1 (zh) * 2024-02-07 2025-08-14 合肥羿科医药有限公司 杂环类化合物、其药物组合物及其应用
CN118084920A (zh) * 2024-02-26 2024-05-28 镇江圣安医药有限公司 五元杂芳环并嘧啶-3-甲酰胺衍生物及其组合物和用途
WO2025214467A1 (zh) * 2024-04-12 2025-10-16 江苏恒瑞医药股份有限公司 氨基取代的杂芳环类化合物、其制备方法及其在医药上的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4564485B2 (ja) * 2003-02-28 2010-10-20 帝人ファーマ株式会社 ピラゾロ[1,5−a]ピリミジン誘導体
BRPI0914404A2 (pt) * 2008-10-31 2019-03-06 Genentech Inc "compostos, composição farmacêutica e método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak quinase em um paciente"
KR102782807B1 (ko) * 2015-11-18 2025-03-14 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물
TW201720828A (zh) * 2015-11-23 2017-06-16 赫孚孟拉羅股份公司 治療性化合物及組合物以及其使用方法
AU2018230737B2 (en) * 2017-03-08 2022-09-22 Takeda Pharmaceutical Company Limited Tyk2 inhibitors, uses, and methods for production thereof
WO2018215390A1 (en) * 2017-05-22 2018-11-29 F. Hoffmann-La Roche Ag Therapeutic compounds and compositions, and methods of use thereof
IL317854A (en) * 2017-07-28 2025-02-01 Takeda Pharmaceuticals Co TYK2 inhibitors and their uses
EP3849981B1 (en) * 2018-09-10 2023-02-01 Eli Lilly and Company Pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus
JP7619951B2 (ja) * 2018-10-15 2025-01-22 武田薬品工業株式会社 Tyk2阻害剤およびその使用
TWI800696B (zh) * 2018-12-10 2023-05-01 美商美國禮來大藥廠 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物
CN114929226B (zh) * 2019-11-08 2024-09-27 温缇克斯生物科学公司 Tyk2假激酶配体

Also Published As

Publication number Publication date
US20220135567A1 (en) 2022-05-05
IL285429A (en) 2021-09-30
EP3920931A1 (en) 2021-12-15
MX2021009555A (es) 2021-10-13
EP3920931A4 (en) 2022-08-10
KR20210124409A (ko) 2021-10-14
BR112021015616A2 (pt) 2021-11-09
AU2020218267A1 (en) 2021-09-30
JP2022519696A (ja) 2022-03-24
SG11202108619SA (en) 2021-09-29
CN113677347A (zh) 2021-11-19
WO2020163778A1 (en) 2020-08-13

Similar Documents

Publication Publication Date Title
JP7635228B2 (ja) Tyk2偽キナーゼリガンド
JP7595582B2 (ja) Tyk2偽キナーゼリガンド
AU2020218267A1 (en) TYK2 pseudokinase ligands
AU2020267661B2 (en) JAK inhibitors
CA3147571A1 (en) Nlrp3 modulators
KR20190067788A (ko) Pde2 억제제로서의 [1,2,4]트리아졸로[1,5-a]피리미딘 화합물
EP4034107A1 (en) Jak inhibitors
CA3150281A1 (en) Jak inhibitors
HK40066192A (zh) Tyk2假激酶配体
HK40066192B (en) Tyk2 pseudokinase ligands
HK40080028B (en) Tyk2 pseudokinase ligands
HK40080028A (en) Tyk2 pseudokinase ligands
HK40064378A (en) Tyk2 pseudokinase ligands

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240205

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250212

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250612

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250902

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251103

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260102

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260323